Latest Manufacturing News

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Locksley Resources has received a non-binding Letter of Interest from the U.S. Export-Import Bank indicating potential financing support of up to US$191 million for its Mojave Project, aligning with U.S. efforts to rebuild domestic critical minerals supply chains.

Aquirian Limited has completed a strategic review of its Wubin Energetics Precinct and entered a framework agreement with Hongda Civil Blasting Group to establish a joint venture for an automated electronic detonator facility in Western Australia.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

FBR Limited unveiled its new DST-enabled Mantis welding robot targeting heavy fabrication sectors while completing key milestones on its Hadrian bricklaying technology and securing a $22 million financing package.

ClearVue Technologies has secured a $4.6 million capital raise and signed major partnerships, setting the stage for commercialisation in 2026 with a robust $60 million project pipeline.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

PARKD Limited has raised $1 million to fund its East Coast expansion, secured a new prefabrication facility in NSW, and landed its first pilot project with McNab Group, marking a pivotal step in its national rollout.

DTI Group secures a major $2 million contract with Rio Tinto for autonomous locomotive tech and re-enters the European market through a new agreement with CAF.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Inhalerx Limited tapped $247,000 from a $38.5 million funding facility to support its clinical trials, while reporting a $310,000 cash burn in operating activities for the September quarter.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.